A journey in synthetic biology: using gene circuit technology in immuno-oncology
Cell & Gene Therapy Insights 2022; 8(7), 849–853
DOI: 10.18609/cgti.2022.131
Published: 25 August 2022
Viewpoint
From Left to right, Timothy Lu, Senti Biosciences, & James Collins, Senti Biosciences and MIT
“The clinical need for synthetic biology is urgent, and the technology has evolved… we can start designing and manufacturing gene circuit-engineered cell and gene therapies at clinical and eventually, commercial scale.”